Abstract: The present invention pertains to an apparatus for mixing mineral acid (e.g. sulfuric acid), and hydroxide bases (e.g. calcium hydroxide) to produce various useful mixtures (e.g. cleaning products, food production, etc.). The present invention provides an apparatus for reproducibly injecting an acid and a base to form a mixture in a controlled environment. In one aspect, the apparatus comprises a chamber having a distribution-blending-cooling dish suspended above the mixing chamber, an acid delivery system for introducing diluted acid into the chamber above the distribution-blending-cooling dish, and a base delivery system for introducing the base into the chamber by passing the base through the distribution-blending dish. The acid is injected preferentially and circumferenceially to provide, enhance, and cause thorough blending. The injectors or eductors are in the mixing chamber, and the blending dish is secondary to the initial introduction of acid.

Abstract: The use of a highly acidic metalated organic acid composition (“HAMO”) as a food additive. The HAMO is used to reduce biological contaminants, and thus preserve, a nutriment. The HAMO is being absorbed in, or adsorbed on, a nutriment material to give a prepared nutriment.

Abstract: A method for increasing the rate of thermal inactivation of a pathogen in a nutriment by contacting the nutriment with an acidulant. A method for extending case shelf-life of a nutriment by contacting the nutriment with an acidulant. The acidulant can be: (a) an acidic, or low pH, solution of sparingly-soluble Group IIA complexes (“AGIIS”); (b) a highly acidic metalated mixture of inorganic acid (“HAMMIA”); (c) a highly acidic metalated organic acid (“HAMO”); (d) a mixture of the above; or (e) an adduct of each of the above. The nutriment can be an animal product, a plant product, a beverage, or a mixture thereof.

Abstract: Growth is improved by utilizing growth enhancement potential methodology to administer a nucleic acid sequence, such as GHRH or an analog, to a female animal, preferably through a parenteral route of administration. Piglets born from sows injected with DNA encoding GHRH are larger, and effects are demonstrated in subsequent pregnancies without additional administration(s) of the vector.

Abstract: An adduct that has an acidic solution of sparingly-soluble Group IIA complexes (“AGIIS”) and at least one additive. The AGIIS can be prepared by mixing a mineral acid (such as sulfuric acid), and a Group IIA hydroxide (such as calcium hydroxide) or a Group IIA salt of a dibasic acid (such as calcium sulfate), or a mixture of the two Group IIA compounds, followed by removing the solid formed. The additives can be an alcohol, an organic acid or a surface active agent. The composition has various uses, including cleaning, food production, decontamination, bioremediation, agricultural application, medical application, and detoxification of substances.

Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.

Abstract: An adduct that has an acidic solution of sparingly-soluble Group IIA complexes (“AGIIS”) and at least one additive. The AGIIS can be prepared by mixing a mineral acid (such as sulfuric acid), and a Group IIA hydroxide (such as calcium hydroxide) or a Group IIA salt of a dibasic acid (such as calcium sulfate), or a mixture of the two Group IIA compounds, followed by removing the solid formed. The additives can be an alcohol, an organic acid or a surface active agent. The composition has various uses, including cleaning, food production, decontamination, bioremediation, agricultural application, medical application, and detoxification of substances.

Abstract: The use of a highly acidic metalated organic acid composition (“HAMO”) as a food additive. The HAMO is used to reduce biological contaminants, and thus preserve, a nutriment. The HAMO is being absorbed in, or adsorbed on, a nutriment material to give a prepared nutriment.

Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.

Abstract: Method for reducing symptoms associated with multiple sclerosis in an animal by administering to the animal an effective amount of an acetylated polymeric mannan derivative.

Abstract: Methods for the treatment of sarcoma, carcinoma and lymphoma in an animal by administering to the animal an effective amount of a polymeric acetylated mannan derivative.

Abstract: Methods of prevention and treatment of infections and infestations in an animal by administering to the animal an effective amount of an acetylated mannan derivative.

Abstract: Methods of treating inflammatory diseases in an animal by administering to the animal an effective amount of a polymeric acetylated mannan derivative of aloe origin.

Abstract: A new class of biologically-active copolymers is provided capable of affecting biological systems in many different ways. The biologically-active copolymers of the present invention also have a wide variety of effects on individual cells. The biologically-active copolymers are also effective against certain microorganisms. The biologically active copolymers of the present invention can be administered to animals to provide specific effects on certain microorganisms that reside in the gut of the animal. A preferred use is administering the biologically active copolymers of the present invention to poultry to reduce the number of Salmonella in the poultry gut. Another preferred use is treatment of surfaces to interfere with the adhesion of microorganisms to the surfaces.

Abstract: A method for promoting wound healing involving initiating and accelerating wound repair and tissue regeneration in an animal by systemic administration of a bioactive polysaccharide derived from aloe vera plant.

Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.

Abstract: A therapeutic medical device is described that is comprised of a dried hydrogel of a hydrophilic-hygroscopic polymer, such as an unmodified or modified polymeric carbohydrate, in the form of a solid foam. The dried hydrogel is prepared by preferably freeze-drying a hydrogel of this polymer in a liquid medium, such as water. The dried hydrogel can be sterilized by radiation or other means so that the sterilized product has a relatively indefinite shelf-life without refrigeration. The resultant dried hydrogel can be transformed into a hydrogel upon absorption of addition liquid medium. The described therapeutic device can serve as a dressing for a wound or lesion, drug delivery system, a hemostatic agent and a biologic response modifier. The described therapeutic device enhances the wound healing rate.

Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.

Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.

Abstract: Acemannan has now been discovered to be a potent inducer of Interleukin 1 (Il-1) and prostaglandin E.sub.2 (PGE.sub.2) production by human peripheral blood adherent cells in culture. Il-1 has been shown to be an important macrophage product and is associated with influencing the activity and production of T lymphocytes, fibroblasts, B lymphocytes and endothelial cells. Acemannan has no demonstrated toxicity, and acts as an adjuvant and immunoenhancer. Administration of an amount of acemannan sufficient to stimulate monocytes and macrophages not only produces Il-1 and PGE.sub.2 but also stimulates phagocytosis, increases antibody production, enhances antiviral activity in the serum and, in those patients with AIDS/ARC, produces defective HIV virus.Acemannan has been shown to affect the rate of virus production in viral vaccine master seed cultures by accelerating the rate of viral replication. In addition, acemannan is a potent adjuvant to viral vaccines in chickens.